[MODY in clinical practice. When and why to consider it?].
It is important to consider in clinical practice the diagnosis of MODY and to characterise the MODY sub-type. Indeed, evolution, clinical consequences and treatment of these forms of diabetes will be different according to the genetic origin of MODY. The main characteristics and consequences in clinical practice of these genetic abnormalities are briefly described, with a particular emphasis on the two most frequent sub-types, MODY-2 and MODY-3, caused by mutations of the enzyme glucokinase and of the transcription factor hepatocyte nuclear factor-1 alpha (HNF-1a) respectively.
Velho
G
G
INSERM U. 561, Hôpital Saint-Vincent-de-Paul F-75674 PARIS Cedex 14. gvelho@infobiogen.fr
D000328:Adult; D002648:Child; D004268:DNA-Binding Proteins; D003924:Diabetes Mellitus, Type 2 / Q000175:diagnosis* / Q000235:genetics; D005260:Female; D005941:Glucokinase / Q000235:genetics; D051537:Hepatocyte Nuclear Factor 1; D051538:Hepatocyte Nuclear Factor 1-alpha; D051539:Hepatocyte Nuclear Factor 1-beta; D006801:Humans; D009154:Mutation; D009687:Nuclear Proteins; D011247:Pregnancy; D014157:Transcription Factors / Q000235:genetics
D004268:DNA-Binding Proteins; C496487:HNF1A protein, human; C496495:HNF1B protein, human; D051538:Hepatocyte Nuclear Factor 1-alpha; D009687:Nuclear Proteins; D014157:Transcription Factors; D051537:Hepatocyte Nuclear Factor 1; D051539:Hepatocyte Nuclear Factor 1-beta; D005941:Glucokinase